China Teacher Who Saved Woman's Life With CPR Now Accused Of Groping After Viral Video
The drama unfolded when a woman suddenly collapsed on a city street. A quick-thinking female doctor from a local hospital immediately began performing cardiopulmonary resuscitation (CPR). As the strenuous procedure continued, the doctor grew tired and called out for assistance.
That's when Pan, a teacher at a local university's medical school with a degree in clinical medicine and CPR training, rode by on his bicycle. Without hesitation, he dismounted and offered his help. Pan and the doctor then took turns administering CPR, with the doctor also monitoring the woman's vital signs and urging her relative to call an ambulance.
Ten minutes later, the woman regained weak breath and pulse and opened her eyes. An ambulance arrived, and she was taken away, accompanied by her relative.
According to SCMP, after the video of Pan and the doctor went viral on social media, some people said that Pan appeared to place his hands in the wrong place.
"He is obviously groping her chest," one online observer said.
"It is better to let a female apply CPR," said another.
Pan, 42, said he was shocked by the negative public reaction.
The incident has ignited a fierce debate across Chinese social media platforms about the risks and rewards of stepping in to help, and the harsh judgment that can follow even the most selfless acts.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Yunus thanks India, global teams for treating Dhaka plane crash victims
A delegation of 21 physicians and nurses from Singapore, China, and India met with Bangladesh's Chief Adviser Professor Muhammad Yunus on Sunday at the State Guest House Jamuna. The international medical teams are currently in Dhaka to provide specialised healthcare services to victims of the recent plane crash at Milestone School and College. During the meeting, Professor Muhammad Yunus expressed his heartfelt gratitude for the rapid response and medical support extended by the healthcare professionals. He commended their dedication and solidarity at a time of national crisis and emphasised the importance of international cooperation in emergency healthcare. "These teams have come not just with their skills, but with their hearts," said Professor Yunus. "Their presence reaffirms our shared humanity and the value of global partnerships in times of tragedy," he added. The medical teams have been working tirelessly alongside local healthcare professionals to ensure critical treatment and trauma care for the injured, many of whom are young children. The Chief Adviser also acknowledged the swift diplomatic coordination that enabled the teams to arrive and begin their work without delay. He assured the visiting professionals of the government's full support in facilitating their mission. The Chief Adviser also urged the physicians to maintain long-term connections with Bangladesh, even virtually, for institutional collaboration, medical education exchange, and sustained engagement in capacity building and innovation in the healthcare sector. He emphasised that such partnerships could lay the foundation for lasting cooperation in public health and emergency preparedness. Health Adviser Nurjahan Begum thanked the physicians and nurses for extending their hand during this difficult time. Professor Sayedur Rahman, special assistant to the Chief Adviser for the Ministry of Health, said that many lives were saved as the foreign physicians rushed immediately. At the meeting, Prof Dr Md. Nasir Uddin, Director, National Institute of Burn & Plastic Surgery (NIBPS), said that it was proven again that doctors are without borders. Ten members from Singapore, eight from China, and four from India attended the meeting. Among others, the Chinese Ambassador to Dhaka, Yao Wen, and the Singapore Head of Mission in Dhaka were also present at the meeting. On July 21, 2025, a Bangladesh Air Force training aircraft, specifically a Chinese-origin F-7 BGI fighter jet, crashed into the Milestone School and College campus in Dhaka's Uttara neighbourhood. The crash resulted in the deaths of at least 27 people and injured over 170 others, mostly students. Bangladesh's interim government declared a national day of mourning on July 22, with flags flown at half-mast in all government offices and educational institutions. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
12 hours ago
- Time of India
US lawmakers press FDA to target knockoff weight-loss drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market-a problem that emerged over the last year. Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity MCA Data Science Degree Leadership PGDM Public Policy Operations Management others Others Product Management healthcare Digital Marketing MBA Technology Project Management CXO Finance Artificial Intelligence Healthcare Data Analytics Management Design Thinking Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details "We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications," they wrote in a letter to FDA commissioner Marty Makary. "Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo The group-spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey-asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the "urgency" of the situation. Live Events A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a "complete and thorough" response to the issues raised in the lawmakers' letter. "Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously," the spokesperson said. "And we are deeply committed to strengthening the oversight of imported products at US ports of entry." In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalise on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage but are no longer permitted to do so after Novo Nordisk and Eli Lilly boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalisations potentially linked to the copycat drugs, but that adverse events are likely being underreported. "We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs," said a spokesperson for Hims & Hers Health, one of the telehealth firms that sells compounded GLP-1s. "We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first." Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments.
Mint
15 hours ago
- Mint
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) More stories like this are available on
